HDAC9 and colorectal cancer: For instance, it has been reported that HDAC inhibitors can decrease the expression of EGFR in colorectal cancer cells [21], and there are studies demonstrating that gefitinib combined with HDAC inhibitors synergistically induced growth inhibition and apoptosis in gefitinib-resistant NSCLC cells [22,23].